- Home
- BRNS vs NOTV Comparison
BRNS vs NOTV Comparison
Compare BRNS & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- NOTV
- Stock Information
- Founded
- BRNS 2016
- NOTV 1974
- Country
- BRNS United Kingdom
- NOTV United States
- Employees
- BRNS N/A
- NOTV N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- NOTV Health Care
- Exchange
- BRNS Nasdaq
- NOTV Nasdaq
- Market Cap
- BRNS 48.3M
- NOTV 57.7M
- IPO Year
- BRNS 2021
- NOTV 1997
- Fundamental
- Price
- BRNS $1.05
- NOTV $1.37
- Analyst Decision
- BRNS Strong Buy
- NOTV Strong Buy
- Analyst Count
- BRNS 1
- NOTV 1
- Target Price
- BRNS $3.00
- NOTV $5.00
- AVG Volume (30 Days)
- BRNS 37.7K
- NOTV 394.8K
- Earning Date
- BRNS 11-05-2025
- NOTV 08-06-2025
- Dividend Yield
- BRNS N/A
- NOTV N/A
- EPS Growth
- BRNS N/A
- NOTV N/A
- EPS
- BRNS N/A
- NOTV N/A
- Revenue
- BRNS $14,969,000.00
- NOTV $505,299,000.00
- Revenue This Year
- BRNS N/A
- NOTV $5.64
- Revenue Next Year
- BRNS N/A
- NOTV $5.16
- P/E Ratio
- BRNS N/A
- NOTV N/A
- Revenue Growth
- BRNS 1766.46
- NOTV 0.85
- 52 Week Low
- BRNS $0.64
- NOTV $1.15
- 52 Week High
- BRNS $2.92
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- BRNS 40.11
- NOTV 32.94
- Support Level
- BRNS $1.08
- NOTV $1.36
- Resistance Level
- BRNS $1.20
- NOTV $1.68
- Average True Range (ATR)
- BRNS 0.09
- NOTV 0.11
- MACD
- BRNS -0.01
- NOTV -0.02
- Stochastic Oscillator
- BRNS 0.00
- NOTV 4.00
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.